Business
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results Canada NewsWire ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Aug. 11, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the second quarter ended\n \n June 30, 2023\n \n . All amounts are expressed in Canadian dollars unless otherwise indicated.\n \n \n \"During our second quarter, we announced exceptional results from our Phase\n \n 2b\n \n clinical trial of EP-104IAR for pain associated with knee osteoarthritis,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"The EP-104IAR Phase\n \n 2b\n \n study is the largest study in the Company's history and we believe that the data is an important indicator on the drug candidate and our underlying diffusion technology. On the strength of the trial's data, we are working on the optimal path forward for EP-104IAR with key opinion leaders and preparing for an End of Phase 2 meeting with the FDA. Concurrently, we have made significant progress with our ongoing Phase\n \n 1b\n \n /2a trial of EP-104GI in eosinophilic esophagitis (\"EoE\"), which is actively recruiting patients. Based on progress to date, this open-label study remains on track for interim data beginning to read out in the third quarter of 2023.\"\n \n \n \n \n Selected Operational and Financial Highlights for the Second Quarter\n \n \n \n \n \n On\n \n June 26, 2023\n \n , Eupraxia announced positive results from its Phase\n \n 2b\n \n clinical trial of EP-104IAR for pain associated with knee osteoarthritis. EP-104IAR met its primary endpoint with a clinically meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in WOMAC Pain at 12 weeks.\n \n \n On\n \n May 18, 2023\n \n , the Company announ...